The global viscosupplementation market is poised for remarkable expansion, with market projections indicating a rise from USD 2,167.3 million in 2024 to an impressive USD 3,777.4 million by 2034. This growth trajectory reflects a compound annual growth rate (CAGR) of 5.7%, driven by increasing demand for effective, non-invasive treatments for osteoarthritis (OA) and other lifestyle-related conditions.
Viscosupplementation, a non-surgical therapy involving hyaluronic acid-based formulations, is gaining widespread popularity as a preferred treatment for osteoarthritis. This treatment offers significant relief from joint pain, particularly in patients with knee osteoarthritis, and is increasingly recognized for its clinical benefits. The rising prevalence of OA, coupled with a growing preference for non-surgical interventions, is fueling the demand for viscosupplements worldwide.
Key Drivers of Market Growth:
- Rising Prevalence of Osteoarthritis: As the global population ages, the incidence of osteoarthritis continues to climb, resulting in heightened demand for viscosupplementation therapies. The therapy offers an appealing solution for those seeking to manage OA symptoms without surgery.
- Growing Preference for Non-Invasive Treatments: Viscosupplementation offers a non-invasive alternative to surgical procedures, making it an attractive option for patients who prioritize quicker recovery times and lower risks associated with invasive surgeries.
- Proven Clinical Benefits: Viscosupplement products have demonstrated significant efficacy in managing knee osteoarthritis, improving patient outcomes, and attracting interest from both healthcare professionals and patients. These benefits further drive the market’s growth.
As the viscosupplementation market expands, there is an increasing focus on research and development of new formulations and innovative delivery methods. These advancements will ensure that patients have access to the latest and most effective treatment options, maintaining the momentum of the market’s growth in the coming years.
Regional Insights:
- Asia Pacific: Dominates the global viscosupplementation market due to its large aging population and preference for non-surgical treatments. The region’s market is driven by cultural norms and a high incidence of osteoarthritis.
- North America: Expected to experience significant growth driven by the rising prevalence of osteoarthritis, well-developed healthcare infrastructure, and increasing demand for non-surgical procedures.
- China: The market in China is forecasted to grow at the highest CAGR of 9.0%, reflecting a substantial increase in demand for viscosupplementation.
- Europe and Japan: Both regions are poised for steady growth, with notable CAGRs of 4.0% and 8.5%, respectively.
Viscosupplementation Trends on the Rise: Uncover the Full Scope with Our In-Depth Report!
Key Market Segments:
- Product Type: Three Injection Viscosupplementation is projected to capture 48.4% of the market share from 2024 to 2034.
- End User: Ambulatory Surgical Centers are expected to hold a significant market share of 31.9% during the same period.
Noteworthy Developments:
- In April 2022, Juniper Biologics and Kolon Life Sciences entered an agreement to license TissueGene-C low dose (TG-C LD), a single intra-articular injection treatment for knee osteoarthritis.
- May 2021 saw the launch of JOYCLU 30 mg intra-articular injection by Ono Pharmaceutical Co., Ltd. and Seikagaku Corporation.
- Anika Therapeutics, Inc. introduced Hyalofast, a hyaluronic acid-based scaffold for cartilage regeneration, at an event hosted by the International Cartilage Regeneration and Joint Preservation Society (ICRS).
Competitive Landscape:
Major players in the viscosupplementation market, including Sanofi S.A., Zimmer Biomet Holdings Inc., and Bioventus LLC, are focusing on developing advanced cross-linked hyaluronic acid products and expanding into new regions to gain a competitive edge.
Prominent Viscosupplementation Manufacturers:
- Anika Therapeutics Inc.
- Fidia Farmaceutici S.p.A.
- Ferring B.V.
- Seikagaku Corporation
- Chugai Pharmaceutical Co., Ltd.
- OrthogenRx Inc.
- Mylan N.V.
Key Segments:
By Product:
- Single Injection
- Three Injection
- Five Injection
By Application:
- Knee Osteoarthritis
- Hip Osteoarthritis
- Shoulder Osteoarthritis
- Others
By End User:
- Hospitals
- Ambulatory Surgical Centers
- Orthopedic Clinics
- Retail Pharmacies
- Online Sales
By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia and Pacific
- Middle East and Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
